# Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

> **NCT00334815** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Lung Adenocarcinoma
- Lung Adenosquamous Carcinoma
- Lung Large Cell Carcinoma
- Lung Squamous Cell Carcinoma
- Minimally Invasive Lung Adenocarcinoma
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **BIOLOGICAL:** Pegfilgrastim
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT00334815
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2006-06-15
- **Primary completion:** 2014-07-01
- **Final completion:** 2027-02-22
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334815, "Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00334815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*